EGFR-driven lung adenocarcinomas coopt alveolar macrophage metabolism and function to support EGFR signaling and growth

Alexandra Kuhlmann-Hogan,Thekla Cordes,Ziyan Xu,Ramya S. Kuna,Kacie A. Traina,Camila Robles-Oteiza,Deborah Ayeni,Elizabeth M. Kwong,Stellar Levy,Anna-Maria Globig,Matthew M. Nobari,George Z. Cheng,Sandra L. Leibel,Robert J. Homer,Reuben J. Shaw,Christian M. Metallo,Katerina Politi,Susan M. Kaech
DOI: https://doi.org/10.1158/2159-8290.cd-23-0434
IF: 28.2
2024-01-21
Cancer Discovery
Abstract:The limited efficacy of currently approved immunotherapies in EGFR-driven lung adenocarcinoma (LUAD) underscores the need to better understand alternative mechanisms governing local immunosuppression to fuel novel therapies. Elevated surfactant and GM-CSF secretion from the transformed epithelium induces tumor-associated alveolar macrophage (TA-AM) proliferation which supports tumor growth by rewiring inflammatory functions and lipid metabolism. TA-AM properties are driven by increased GM-CSF—PPARγ signaling and inhibition of airway GM-CSF or PPARγ in TA-AMs suppresses cholesterol efflux to tumor cells, which impairs EGFR phosphorylation and restrains LUAD progression. In the absence of TA-AM metabolic support, LUAD cells compensate by increasing cholesterol synthesis, and blocking PPARγ in TA-AMs simultaneous with statin therapy further suppresses tumor progression and increases proinflammatory immune responses. These results reveal new therapeutic combinations for immunotherapy resistant EGFR-mutant LUADs and demonstrate how cancer cells can metabolically co-opt TA-AMs through GM-CSF—PPARγ signaling to provide nutrients that promote oncogenic signaling and growth.
oncology
What problem does this paper attempt to address?